---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-069935"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T04:06:09.567359+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veru refocuses on sabizabulin for COVID/influenza; terminates prostate cancer trial, pauses two assets

## Summary
- Terminating Phase 3 VERACITY trial of sabizabulin in prostate cancer; pausing Phase 2 Veru-100 and zuclomiphene development.
- Plans Phase 3 confirmatory study of sabizabulin for hospitalized moderate/severe COVID-19 patients at high risk for ARDS.
- Plans Phase 3 study of sabizabulin for hospitalized influenza patients at high risk for ARDS.
- Updated Phase 3 ENABLAR-2 study of enobosarm + abemaciclib for second-line metastatic breast cancer; rolling ARTEST into it pending FDA/Lilly approval.
- Cash conservation measures including personnel reduction; prior FDA denial of EUA for sabizabulin on March 2, 2023.

## SEC filing metadata
- accession: 0001193125-23-069935
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312523069935/0001193125-23-069935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312523069935/d254341d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-069935
- JSON: https://secwatch.observer/filing/0001193125-23-069935.json
- Plain text: https://secwatch.observer/filing/0001193125-23-069935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.